231 related articles for article (PubMed ID: 9010215)
21. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
22. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth.
Murphy GA; Solski PA; Jillian SA; Pérez de la Ossa P; D'Eustachio P; Der CJ; Rush MG
Oncogene; 1999 Jul; 18(26):3831-45. PubMed ID: 10445846
[TBL] [Abstract][Full Text] [Related]
23. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
[TBL] [Abstract][Full Text] [Related]
24. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
25. The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function.
Oertli B; Han J; Marte BM; Sethi T; Downward J; Ginsberg M; Hughes PE
Oncogene; 2000 Oct; 19(43):4961-9. PubMed ID: 11042683
[TBL] [Abstract][Full Text] [Related]
26. Mutations that abolish the ability of Ha-Ras to associate with Raf-1.
Shirouzu M; Koide H; Fujita-Yoshigaki J; Oshio H; Toyama Y; Yamasaki K; Fuhrman SA; Villafranca E; Kaziro Y; Yokoyama S
Oncogene; 1994 Aug; 9(8):2153-7. PubMed ID: 8036000
[TBL] [Abstract][Full Text] [Related]
27. Alternate mechanisms of ras activation are complementary and favor and formation of ras-GTP.
Patel G; MacDonald MJ; Khosravi-Far R; Hisaka MM; Der CJ
Oncogene; 1992 Feb; 7(2):283-8. PubMed ID: 1549350
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution.
Kimmelman A; Tolkacheva T; Lorenzi MV; Osada M; Chan AM
Oncogene; 1997 Nov; 15(22):2675-85. PubMed ID: 9400994
[TBL] [Abstract][Full Text] [Related]
29. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
30. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
31. An essential role for Rac in Ras transformation.
Qiu RG; Chen J; Kirn D; McCormick F; Symons M
Nature; 1995 Mar; 374(6521):457-9. PubMed ID: 7700355
[TBL] [Abstract][Full Text] [Related]
32. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Ramírez de Molina A; Penalva V; Lucas L; Lacal JC
Oncogene; 2002 Jan; 21(6):937-46. PubMed ID: 11840339
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
[TBL] [Abstract][Full Text] [Related]
34. R-Ras promotes tumor growth of cervical epithelial cells.
Rincón-Arano H; Rosales R; Mora N; Rodriguez-Castañeda A; Rosales C
Cancer; 2003 Feb; 97(3):575-85. PubMed ID: 12548599
[TBL] [Abstract][Full Text] [Related]
35. The Saccharomyces cerevisiae gene product SDC25 C-domain functions as an oncoprotein in NIH3T3 cells.
Barlat I; Schweighoffer F; Chevallier-Multon MC; Duchesne M; Fath I; Landais D; Jacquet M; Tocque B
Oncogene; 1993 Jan; 8(1):215-8. PubMed ID: 7999142
[TBL] [Abstract][Full Text] [Related]
36. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of the guanine nucleotide exchange reaction of Ras GTPase--evidence for a GTP/GDP displacement model.
Zhang B; Zhang Y; Shacter E; Zheng Y
Biochemistry; 2005 Feb; 44(7):2566-76. PubMed ID: 15709769
[TBL] [Abstract][Full Text] [Related]
38. Ras activation in response to phorbol ester proceeds independently of the EGFR via an unconventional nucleotide-exchange factor system in COS-7 cells.
Rubio I; Rennert K; Wittig U; Beer K; Dürst M; Stang SL; Stone J; Wetzker R
Biochem J; 2006 Sep; 398(2):243-56. PubMed ID: 16709153
[TBL] [Abstract][Full Text] [Related]
39. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
40. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism.
Wang HG; Millan JA; Cox AD; Der CJ; Rapp UR; Beck T; Zha H; Reed JC
J Cell Biol; 1995 May; 129(4):1103-14. PubMed ID: 7744959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
